GILD in Q1 2026: Growth, Acquisitions, and a Pipeline That Keeps the Dialog Open

Key numbers at a glance

Gilead Sciences, Inc. (GILD) logged a first quarter in which total revenues reached about $7.0 billion, up roughly 4% year over year. Excluding Veklury, product sales rose 8% to $6.8 billion, underscoring strength in the core portfolio even as the company cycles through the post-pandemic swing away from remdesivir.

HIV product sales rose about 10% to $5.0 billion, a line item that looks increasingly like the backbone of the franchise as other areas shift. The company also reported a GAAP diluted EPS of $1.61 and a Non-GAAP diluted EPS of $2.03 for the quarter. Management highlighted that total first-quarter 2026 product sales were up 5% to $6.9 billion, with ex-Veklury growth of 8% to $6.8 billion.

On the cash front, as of March 31, 2026, GILD held roughly $8.6 billion in cash, cash equivalents and marketable debt securities, down from $10.6 billion at year-end. The drift was financed by $2.8 billion in debt repayments, $1.0 billion in dividends and about $419 million of share repurchases, offset by roughly $2.5 billion of operating cash flow. The balance sheet remains sturdy, even as the company leans into a more diversified growth profile.

Where the money came from and what moved it

Total revenue growth was broad-based enough to buoy investor sentiment, with HIV driving a solid portion of the gains. Ex-Veklury product sales, which exclude the remdesivir franchise, rose to about $6.8 billion, driven by higher demand and pricing in HIV therapies, while other legacy segments faced headwinds tied to lower sales in areas like HCV and Cell Therapy products.

HIV product sales advanced 10% year over year to roughly $5.0 billion, reflecting continued strength in demand and pricing dynamics. The press release attributes the overall topline performance to a combination of higher sales volume and favorable pricing, supported by ongoing momentum in the base business.

Additionally, management framed the first-quarter results against ongoing portfolio dynamics—successes in the near term with products such as Trodelvy and Livdelzi (a nod to the company’s readjusted mix) while acknowledging that some lines faced pressure. In total, first-quarter 2026 product sales were reported at about $6.9 billion, with ex-Veklury sales at $6.8 billion.

Management’s view, strategy, and what it portends

CEO Daniel O’Day framed the quarter as evidence of a durable growth trajectory, noting 8% year-over-year growth in the base business and 10% growth in HIV. The company signaled an ambitious 2026 product-launch cadence—up to four potential launches and five Phase 3 updates anticipated within the year—bolstered by strategic acquisitions of Arcellx, Ouro Medicines and Tubulis. With these moves, GILD aims to broaden its platform in oncology and inflammation beyond its HIV franchise.

The company also cited Yeztugo (a new launch) as a growth driver and indicated it is actively expanding its pipeline via acquisitions while maintaining a strong financial compass. Importantly, management raised its full-year revenue forecast, signaling confidence that the current quarter’s performance is part of a broader plan rather than a one-off data point.

From an analyst’s lens, the EPS figures provide a clean read on profitability: GAAP EPS of $1.61 and Non-GAAP EPS of $2.03 reflect a mix of higher product sales, favorable net gains on investments, and the offset of higher tax and SG&A costs. Investors will watch how these earnings per share figures compare to the EPS consensus as the year unfolds. The lack of a material earnings surprise in the short term may actually be the news—on a relative basis, the year-over-year uplift coupled with a raised revenue forecast keeps the stock in the debate for expansion upside rather than a one-quarter pop.

Outlook for GILD and sector peers

By elevating its revenue forecast and signaling a robust pipeline, Gilead is sending a message to peers: diversify, leverage smarter launches, and accelerate through strategic M&A. The bar for the rest of the sector remains anchored in the same theme—maintain growth in core franchises (here, HIV) while expanding into high-potential areas (oncology, inflammation) via acquisitions and internal development.

The results also imply a prudent path for capital allocation: sustaining a healthy cash flow profile while maintaining optionality through acquisitions and strategic investments. The balance sheet remains lean relative to the cash flow generated, though cash is gradually deployed through dividends and buybacks alongside debt repayment. How peers react—whether they emulate this cadence or pivot more aggressively into pipeline-driven growth—will shape the sector’s tone in late 2026.

Conclusion: a measured, forward-looking quarter

GILD’s first quarter of 2026 offers a coherent narrative: a growing top line, a dominant HIV franchise, and a thoughtful expansion into new therapeutic areas. While the results do not hinge on a dramatic earnings surprise, they align with a plan that emphasizes revenue growth, EPS resilience, and a pipeline that could shift the center of gravity for the company over the next several years.

For sector peers, the message is clear: the era of “just a bigger pipeline” is giving way to “a bigger, better pipeline with tied-to-market launches.” If Gilead’s cadence holds—earnings growth tied to product excellence, a deliberate acquisition strategy, and a disciplined cash plan—the company could emerge as a benchmark for how large biopharma balances portfolio diversification with shareholder value through 2026 and beyond.